Pharmacotherapy for nontuberculous mycobacterial pulmonary disease.
Mycobacterium abscessus
Mycobacterium avium
Mycobacterium xenopi
NTM
inhaled amikacin
nontuberculous mycobacterial pulmonary disease
Journal
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
ISSN: 1535-2900
Titre abrégé: Am J Health Syst Pharm
Pays: England
ID NLM: 9503023
Informations de publication
Date de publication:
07 03 2022
07 03 2022
Historique:
pubmed:
18
11
2021
medline:
17
3
2022
entrez:
17
11
2021
Statut:
ppublish
Résumé
To provide an updated review of the diagnosis and pharmacotherapy of nontuberculous mycobacteria pulmonary disease (NTM-PD) and summarize guideline recommendations for an interdisciplinary treatment approach. A systemic approach was taken in which all articles in English in MEDLINE and PubMed were reviewed. The US National Library of Medicine's DailyMed database was used to assess drug package inserts. Analysis of NTM treatment guidelines is summarized in the article with a focus on medications, dosing, interactions, and medication monitoring. It is critical to manage patients with NTM with a multidisciplinary team approach. Treatment is prolonged and expensive, and the potential for drug toxicity, adverse effects, and drug interactions requires monitoring. Clinical pharmacists play a role in the management of NTM.
Identifiants
pubmed: 34788375
pii: 6425724
doi: 10.1093/ajhp/zxab422
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437-445Informations de copyright
© American Society of Health-System Pharmacists 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.